Clinical approach to the patient with neurogenetic disease

Bennett, 2009 Bird, 2002, Approaches to the patient with neurogenetic disease. Neurologic Clinics, Neurogenetics, 20, 619 Bird, 1982, The porphria, plumbism, pottery puzzle, JAMA, 247, 813, 10.1001/jama.1982.03320310061032 Cranfurd, 2012, Genetic counseling and genetic testing for neurogenetic disorders Dorschner, 2013, Actionable, pathogenic incidental findings in 1,000 participants’ exomes, Am J Hum Genet, 93, 631, 10.1016/j.ajhg.2013.08.006 Eng, 2001, Safety and efficacy of recombinant human α-galactosidase: a replacement therapy in Fabry's disease, N Engl J Med, 345, 9, 10.1056/NEJM200107053450102 Ku, 2012, Exome sequencing: dual role as a discovery and diagnostic tool, Ann Neurol, 71, 5, 10.1002/ana.22647 Lipe, 2009, Late onset Huntington disease: clinical and genetic characteristics of 34 cases. J Neurol, Sciences, 276, 159 Miller, 2010, Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies, Am J Hum Genet, 86, 749, 10.1016/j.ajhg.2010.04.006 Novarino, 2014, Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders, Science, 343, 506, 10.1126/science.1247363 Nussbaum, 2007 Rosenberg, 2014 Shen, 2009, Microarray-based genomic DNA profiling technologies in clinical molecular diagnostics, Clinic Chem, 55, 659, 10.1373/clinchem.2008.112821 Uhlmann, 2009 Van der Ploeg, 2008, Pompe's disease, Lancet, 372, 1342, 10.1016/S0140-6736(08)61555-X Wood, 2012